Inflammation in the central nervous system (CNS) contributes to disease pathologies by
disrupting the integrity of the blood–brain barrier (BBB). Tight junctions (TJ) are a key …

Ischemic stroke is a clinically common cerebrovascular disease whose main risks include
necrosis, apoptosis and cerebral infarction, all caused by cerebral ischemia and reperfusion …

Despite recent advances in recanalization therapy, mechanical thrombectomy will never be
a treatment for every ischemic stroke because access to mechanical thrombectomy is still …

Hyperglycemia has been shown to counterbalance the beneficial effects of tissue
plasminogen activator (tPA) and increase the risk of intracerebral hemorrhage in ischemic …

Cucurbitacin B (CuB) has been demonstrated to possess anti-inflammatory and
antioxidative properties. However, the effect of CuB on cerebral ischemia/reperfusion (I/R) …

Background: Thrombolysis with tissue plasminogen activator (tPA) remains the only
approved drug therapy for acute ischemic stroke. However, delayed tPA treatment is …

Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is currently the
only FDA-approved drug for acute ischemic stroke. However, its administration is still limited …

JLX001, a new dihydrochloride of Cyclovirobuxine D (CVB-D), has bioactivities against
ischemia injury. The blood-brain barrier (BBB) disruption is involved in the pathogeneses of …

Protective effect of edaravone on blood-brain barrier (BBB) in experimental cerebral
infarction rats was investigated. SD rats were prepared as the permanent middle cerebral …

Cerebral ischemia is a cerebrovascular disease with high morbidity and mortality that poses
a significant burden on society and the economy. About 60% of cerebral ischemia is caused …